Navigation Links
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Date:10/12/2011

h its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  Neuralstem's first small molecule compound, NSI-189 is currently in a Phase I FDA-approved safety trial in major depressive disorder.  The Phase Ib portion of the trial, in depressed patients, is expected to commence later this year. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For up-to-date information on the clinical trial for ALS and other Neuralstem cell therapy and pharmaceutical treatments in development, visit www.neuralstem.com

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ ma
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
2. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
3. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
4. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
5. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
6. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
7. Neuralstem Completes $5.25 Million Financing
8. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
9. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... LONDON , May 27, 2015  The ... provides comprehensive understanding and unprecedented access to the ... worlds leading healthcare companies during 2014. ... gain insight into the partnering activities of the ... view all the partnering and alliances deals announced ...
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) has ... Cancer Monoclonal Antibodies Market Outlook 2020" report ... to dominate the breast cancer monoclonal antibody segment ... Herceptin has been able to dominate this segment ... cancer cells become recalcitrant and relapsed condition could ...
(Date:5/27/2015)... , May 27, 2015 /CNW/ - CQDM, Brain Canada ... to $8.5M to six (6) multi-disciplinary and multi-provincial research ... within their Focus on Brain strategic initiative. To this ... involved as in-kind contributions. This exciting announcement was made ... for Neuroscience in the presence of Inez Jabalpurwala, President ...
(Date:5/27/2015)... Empowering biomedical researchers with richer, ... Inc. today announced its MR Compatible Small Animal ... Scanner uses silicon photomultiplier detector technology, so it ... from manufacturers like Bruker and Agilent,” said James ... “This enables simultaneous PET and MRI data acquisition ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10Cubresa Launches Simultaneous PET/MRI Technology 2
... Campbell Alliance, the leading management consulting firm specializing in ... launched a new practice area focused on medical affairs. ... practice enables the firm to specifically target the evolving needs ... firm has done work in the area of medical affairs ...
... OSLO, Norway, June 17 , ... Improve Remission Rates and,Reduce Short-Term Mortality Compared to Previous ... (OSE: CLAVIS) today announces positive final results,from a Phase ... in patients with late-stage acute myeloid leukaemia (AML). In ...
... Nearly 200 Quantitative Immunoassays for Discovery and Validation ... Texas, June 17 Rules-Based Medicine, Incorporated (RBM), ... announced the availability of the most comprehensive collection ... efficacy and efficiency in drug and diagnostic development. ...
Cached Biology Technology:Campbell Alliance Launches New Practice Area Focused on Medical Affairs 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... 2015  Technology is rapidly advancing, outpacing enterprises, ability ... cloud. Passwords and their management are soon to be ... specifications such as those developed by the FIDO Alliance™. ... presents for BYOD, COPE, IoT, and mobile payments, the ... In response to the call for ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... but treatable kind of addiction. However, not all people who ... stop taking drugs. A new study shows that, in the ... of craving, an antisocial personality type and previous heroin abuse ... into the habit. Ana Lpez, lead author of the ...
... on Skin of Amphibians May Protect Against Lethal Fungus ... bacteria on the skin of salamanders could help protect ... a lethal skin disease. The researchers from James ... report their findings in the November 2009 issue of ...
... stress in humans has been implicated in heart disease, weight ... Extreme environments, a source of chronic stress, present a ... exception. Yet, some species somehow manage to survive, and ... article by Dr. Yuri Springer in the November issue of ...
Cached Biology News:Why can't some people give up cocaine? 2Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4The benefits of stress ... in plants 2
... Polymerase is the most thoroughly characterized enzyme ... to its overall utility and efficacy. , ... for PCR applications. , It is ... ,, AmpliTaq DNA Polymerase is a 94 ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... GCpro Taq DNA Polymerase is a ... advantages for all PCR applications. GCpro Taq ... clone expressed in E. coli, containing the ... The enzyme includes a highly processive 5'-3' ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: